Sage Therapeutics
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2010-01-01
- Employees
- 10
- Market Cap
- $495.1M
- Website
- http://www.sagerx.com
- Introduction
Sage Potash Corp is engaged in the acquisition, exploration, and development of mineral properties. Its principal business activity is the acquisition, exploration, and development of potash mineral properties. It holds interest in Sage Plain Potash property. The projects of the company include Sage Potash and Sage Lithium.
Zuranolone Pharmacokinetics (PK) and Safety Study Adolescent Participants With Major Depressive Disorder (MDD)
- First Posted Date
- 2022-12-19
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Sage Therapeutics
- Target Recruit Count
- 19
- Registration Number
- NCT05655507
- Locations
- 🇺🇸
Sage Investigational Site, Cincinnati, Ohio, United States
A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Huntington's Disease
- First Posted Date
- 2022-12-19
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Sage Therapeutics
- Target Recruit Count
- 300
- Registration Number
- NCT05655520
- Locations
- 🇨🇦
Sage Investigational Site, Toronto, Ontario, Canada
An Open-Label Study Evaluating Brexanolone in Adults With Tinnitus
- First Posted Date
- 2022-12-09
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Sage Therapeutics
- Target Recruit Count
- 10
- Registration Number
- NCT05645432
- Locations
- 🇺🇸
Sage Investigational Site, Iowa City, Iowa, United States
A Study to Evaluate the Effects of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (AD)
- Conditions
- Interventions
- First Posted Date
- 2022-11-17
- Last Posted Date
- 2024-08-12
- Lead Sponsor
- Sage Therapeutics
- Target Recruit Count
- 174
- Registration Number
- NCT05619692
- Locations
- 🇵🇷
Sage Investigational Site, Bayamon, Puerto Rico
A Study to Evaluate the Long-term Safety and Tolerability of SAGE-324 in Participants With Essential Tremor
- First Posted Date
- 2022-05-09
- Last Posted Date
- 2024-10-14
- Lead Sponsor
- Sage Therapeutics
- Target Recruit Count
- 750
- Registration Number
- NCT05366751
- Locations
- 🇺🇸
Sage Investigational Site, Spokane, Washington, United States
28-Day Study of SAGE-718 on Functioning Capacity in Participants With Huntington's Disease
- First Posted Date
- 2022-05-03
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Sage Therapeutics
- Target Recruit Count
- 69
- Registration Number
- NCT05358821
- Locations
- 🇺🇸
Sage Investigational Site, Houston, Texas, United States
A Study to Evaluate the Effects of SAGE-718 in Participants With Parkinson's Disease Cognitive Impairment
- Conditions
- Interventions
- First Posted Date
- 2022-04-08
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- Sage Therapeutics
- Target Recruit Count
- 86
- Registration Number
- NCT05318937
- Locations
- 🇺🇸
Sage Investigational Site, Madison, Wisconsin, United States
Study to Evaluate SAGE-324 in Participants With Essential Tremor
- First Posted Date
- 2021-12-29
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- Sage Therapeutics
- Target Recruit Count
- 147
- Registration Number
- NCT05173012
- Locations
- 🇺🇸
Sage Investigational Site, Spokane, Washington, United States
A Study to Evaluate the Effect of SAGE-718 on Cognitive Function in Participants With Huntington's Disease (HD)
- First Posted Date
- 2021-11-04
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Sage Therapeutics
- Target Recruit Count
- 189
- Registration Number
- NCT05107128
- Locations
- 🇬🇧
Sage Investigational Site, Southampton, United Kingdom
A Study To Assess The Safe-Use Conditions For Administration of ZULRESSO® in a Home Setting
- First Posted Date
- 2021-09-28
- Last Posted Date
- 2023-07-19
- Lead Sponsor
- Sage Therapeutics
- Target Recruit Count
- 52
- Registration Number
- NCT05059600
- Locations
- 🇺🇸
Sage Investigational Site, League City, Texas, United States
🇺🇸Virtual Site (recruiting nationwide), Culver City, California, United States